A low rate of central nervous system progression in a phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon alfa 2-B for metastatic malignant melanoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 5, 2005, Pages 479-484

  Ready, Neal ^a   Aronson, Frederick ^b   Wanebo, Harold ^c   Kennedy, Theresa ^d  

^a RHODE ISLAND HOSPITAL   (United States)

^b Maine Center for Cancer Medicine and Blood Disorders   (United States)

^c ROGER WILLIAMS MEDICAL CENTER   (United States)

^d Brown University Oncology Group   (United States)

Author keywords

Brain metastases; Chemobiotherapy; Malignant melanoma; Temozolomide

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; INTERLEUKIN 2; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BRAIN METASTASIS; CANCER REGRESSION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DEHYDRATION; DOSE RESPONSE; ELECTROLYTE DISTURBANCE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; INFECTION; KIDNEY FAILURE; MALE; MELANOMA; NEUTROPENIA; OUTPATIENT CARE; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DACARBAZINE; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON ALFA-2B; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED;

EID: 26444545392     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000164006.72694.1b     Document Type: Article

References (23)

1. Lotze MT, Dallal RM, Kirkwood JM, et al. Cutaneous melanoma. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 6th ed. Philadelphia: Lippincott, Williams & Wilkins; 2001:2012-2069.
2. Delprete SA, Mauer LH, O'Donell J. Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. Cancer Treat Rep. 1984;69:1403-1411.
3. Buzaid AC, Legha S, Winn R, et al. Cisplatin, vinblastine, and dacarbazine (CVD) versus dacarbazine alone in metastatic melanoma: preliminary results of a phase II cancer community oncology program (CCOP) trial. Proc Am Soc Clin Oncol. 1993;12:389.
4. Chapman PB, Einhorn LH, Meyers ML. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745-2751.
5. Kirkwood JM, Strawderman MH, Ernstoff MS. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Group Trial EST 1684. J Clin Oncol. 1996;14:7-17.
6. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18:2444-2458.
7. Kirkwood JM, Ibrahim JG, Sosman JA. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19:2370-2380.
8. Rosenberg SA, Yang JC, Topalian SL. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA. 1994;271:907-913.
9. Legha SS, Ring S, Eton O, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alpha, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol. 1998;16:1752-1759.
10. McDermott DF, Mier JW, Lawrence DP, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, (CVD), interleukin-2 (IL-2) and interferon alpha-2B (IFN) in patients with metastatic melanoma. Clin Cancer Res. 2000;6:2201-2208.
11. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic melanoma. J Clin Oncol. 2000;18:158-166.
12. Summers U, Middleton MR, Calvert H, et al. Effect of temozolomide on central nervous system relapse in relapse in patients with advanced melanoma. Proc Am Soc Clin Oncol. 1999;18:531a.
13. Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol. 2004;22:2101-2107.
14. Eton O, Legha SS, Bedikian A, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002;20:2045-2052.
15. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol. 1999;17:968-975.
16. Atkins MB, Lee S, Flaherty LA, et al., for the US Melanoma Intergroup. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2, and interferon alpha-2b versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol. 2003;22:708.
17. Keilholz U, Punt CJ, Gore M, et al., for the EORTC Melanoma Group. Dacarbazine, cisplatin and IFN-alpha-2b with or without IL-2 in advanced melanoma: final analysis of EORTC randomized phase III trial 18951. Proc Am Soc Clin Oncol. 2003;22:708.
18. Del Vecchio M, Bajetta E, Vitali M, et al. Multicenter phase III randomized trial of cisplatin, vindesine, and dacarbazine (CVD) versus CVD plus subcutaneous interleukin-2 and interferon-alpha-2b in metastatic melanoma patients. Proc Am Soc Clin Oncol. 2003;22:709.
19. Paul M J, Summers Y, Calvert AH, et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res. 2002;12:175-178.
20. Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma. J Clin Oncol. 2004;22:1118-1125.
21. Atkins MB, O'Boyle KR, Sosman JA, et al. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol. 1994;12:1553-1560.
22. Mitchell MS. Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J Clin Oncol. 1989;7: 1701.
23. Atkins MB, Gollob JA, Sosman JA, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha2B in patients with metastatic melanoma. Clin Cancer Res. 2002;8:3075-3081.